Potassium citrate

Uses and Indications

Potassium citrate is indicated for the management of the following conditions:

• Renal Tubular Acidosis (RTA) with calcium stones.

• Hypocitraturic Calcium Oxalate Nephrolithiasis of any etiology.

• Uric Acid Lithiasis with or without calcium stones.

Potassium citrate is available in both tablet and extended-release tablet forms. There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

Therapy with Potassium Citrate should be initiated based on the severity of hypocitraturia as follows:

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), the recommended starting dosage is 60 mEq per day. This can be administered as either 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals, within 30 minutes after meals, or at bedtime.

For patients with mild to moderate hypocitraturia (urinary citrate > 150 mg/day), the recommended starting dosage is 30 mEq per day. This can be given as 15 mEq two times per day or 10 mEq three times per day, also taken with meals, within 30 minutes after meals, or at bedtime.

Potassium Citrate is available in both tablet and extended-release forms. It is important to ensure that the medication is taken as directed to optimize therapeutic outcomes.

Contraindications

Patients with hyperkalemia or conditions predisposing them to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, should not use this medication.

Additionally, it is contraindicated in patients who have conditions that may cause arrest or delay in tablet passage through the gastrointestinal tract, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture.

Patients with peptic ulcer disease, active urinary tract infection, or renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min) are also advised against using this medication.

Warnings and Precautions

Hyperkalemia

Potassium citrate administration can lead to hyperkalemia and cardiac arrest in patients with impaired mechanisms for excreting potassium. This condition can develop rapidly and may be asymptomatic. The use of potassium citrate is contraindicated in patients with chronic renal failure or any condition that impairs potassium excretion, such as severe myocardial damage or heart failure.

Gastrointestinal Lesions

In cases of severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately. The possibility of bowel perforation or obstruction must be investigated.

General Precautions

No specific general precautions have been provided.

Laboratory Tests

No specific laboratory tests have been recommended.

Emergency Medical Help

No specific instructions for obtaining emergency medical help have been provided.

Discontinuation Instructions

Patients should stop taking potassium citrate and contact their doctor if they experience severe vomiting, abdominal pain, or gastrointestinal bleeding. Immediate discontinuation of the medication is advised, along with an investigation for potential bowel perforation or obstruction.

Side Effects

Minor gastrointestinal complaints are the most commonly reported adverse reactions associated with potassium citrate. These include:

• Abdominal discomfort

• Vomiting

• Diarrhea

• Loose bowel movements

• Nausea

Serious adverse reactions can occur, particularly in patients with impaired mechanisms for excreting potassium. These include:

• Hyperkalemia: Potassium citrate administration can lead to hyperkalemia and cardiac arrest. This condition can develop rapidly and may be asymptomatic, making it potentially fatal. The use of potassium citrate is contraindicated in patients with chronic renal failure or any condition that impairs potassium excretion, such as severe myocardial damage or heart failure.

• Gastrointestinal lesions: In cases of severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately. The possibility of bowel perforation or obstruction should be investigated.

Additional considerations for adverse reactions include:

• Patients with pre-existing hyperkalemia or conditions that predispose them to hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, or extensive tissue breakdown.

• Patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture.

• Patients with peptic ulcer disease or active urinary tract infections.

• Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 mL/kg/min.

In cases of overdosage, hyperkalemia is typically asymptomatic and may only be indicated by increased serum potassium levels and characteristic electrocardiographic changes, such as peaking of the T-wave, loss of the P-wave, depression of the S-T segment, and prolongation of the QT interval. Late manifestations can include muscle paralysis and cardiovascular collapse due to cardiac arrest.

Drug Interactions

Concomitant administration of potassium citrate with certain drug classes may lead to significant interactions, primarily related to hyperkalemia and gastrointestinal irritation.

Pharmacokinetic Interactions

• Potassium-Sparing Diuretics: The use of potassium-sparing diuretics alongside potassium citrate should be avoided, as this combination can result in severe hyperkalemia.

Pharmacodynamic Interactions

• Drugs that Slow Gastrointestinal Transit Time: Agents such as anticholinergics may increase gastrointestinal irritation when used with potassium salts, potentially exacerbating discomfort.

• Renin-Angiotensin-Aldosterone Inhibitors: Patients taking these inhibitors should be monitored for hyperkalemia, as the risk may be heightened when combined with potassium citrate.

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): The concurrent use of NSAIDs with potassium citrate also necessitates monitoring for hyperkalemia, as this combination may increase potassium levels in the body.

In summary, careful consideration and monitoring are advised when potassium citrate is prescribed alongside these drug classes to mitigate the risk of adverse effects.

Pediatric Use

Safety and effectiveness of Potassium Citrate in pediatric patients have not been established. This includes all formulations, such as tablets and extended-release tablets. There are no available data to support its use in children.

Geriatric Use

Clinical studies of potassium citrate extended-release tablets have not specifically included sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Elderly patients may be more sensitive to the effects of potassium citrate, particularly regarding the risk of hyperkalemia.

The risk of hyperkalemia may be increased in elderly patients due to age-related decline in renal function. Potassium citrate administration can lead to hyperkalemia and cardiac arrest, especially in patients with impaired mechanisms for excreting potassium. Therefore, it is recommended to closely monitor serum electrolytes, including potassium levels, in elderly patients receiving potassium citrate.

Dosage adjustments may be necessary for elderly patients, particularly those with reduced kidney function or other comorbidities that may affect potassium excretion. Additionally, elderly patients may exhibit increased sensitivity to side effects, necessitating careful consideration of the risks versus benefits of potassium citrate therapy in this population. Caution should be exercised when administering potassium citrate to elderly patients, particularly those with chronic renal failure or other conditions that impair potassium excretion. These considerations underscore the importance of individualized treatment and monitoring in geriatric patients receiving potassium citrate.

Pregnancy

Potassium citrate has not been studied in animal reproduction, and it is unknown whether it can cause fetal harm or affect reproductive capacity when administered to pregnant patients. Due to the lack of data, potassium citrate should only be given to pregnant patients if clearly needed. It is classified as Pregnancy Category C, indicating that risk cannot be ruled out. Healthcare professionals are advised to weigh the potential benefits against the risks when considering the use of potassium citrate in this population.

Lactation

Potassium citrate is excreted in human milk, with the normal potassium ion content of breast milk being approximately 13 mEq/L. However, it is not known whether potassium citrate affects this potassium content. Due to the lack of specific studies on animal reproduction and the potential for unknown effects on breastfed infants, potassium citrate should only be administered to lactating mothers if clearly needed. Caution is advised, and healthcare providers should weigh the benefits against potential risks when considering its use in breastfeeding women.

Renal Impairment

In patients with renal impairment, the administration of potassium citrate, including both tablet and extended-release forms, poses a significant risk of hyperkalemia. This condition can lead to severe complications, including cardiac arrest, and may develop rapidly and without symptoms. Therefore, the use of potassium citrate is contraindicated in individuals with chronic renal failure or any other conditions that compromise potassium excretion, such as severe myocardial damage or heart failure.

Healthcare professionals should exercise caution when considering potassium citrate for patients with impaired renal function. Regular monitoring of potassium levels is essential to prevent potentially fatal outcomes associated with hyperkalemia. It is imperative to avoid the use of potassium citrate in these populations to ensure patient safety and mitigate the risk of serious adverse effects.

Hepatic Impairment

Patients with hepatic impairment have no specific information regarding dosage adjustments, special monitoring, or precautions when using Potassium Citrate in any of its forms, including tablets and extended-release formulations. The available data does not provide guidance on the management of these patients, indicating that no alterations to standard dosing or monitoring protocols are recommended based on hepatic function.

Overdosage

In cases of overdose, hyperkalemia may develop rapidly and can be asymptomatic, particularly in patients with impaired mechanisms for excreting potassium. This condition can lead to serious complications, including cardiac arrest. Symptoms of hyperkalemia may manifest as increased serum potassium concentrations and characteristic electrocardiographic changes, such as peaking of the T-wave, loss of the P-wave, depression of the S-T segment, and prolongation of the QT interval. Late manifestations may include muscle paralysis and cardiovascular collapse.

Management of hyperkalemia involves several critical interventions:

1. Monitoring: Patients should be closely monitored for arrhythmias and electrolyte changes.

2. Medication Adjustment: It is essential to eliminate medications containing potassium and those with potassium-sparing properties, including potassium-sparing diuretics, angiotensin receptor blockers (ARBs), ACE inhibitors, NSAIDs, and certain nutritional supplements.

3. Dietary Restrictions: Foods high in potassium should be eliminated from the diet. This includes items such as almonds, apricots, bananas, beans (lima, pinto, white), cantaloupe, canned carrot juice, figs, grapefruit juice, halibut, milk, oat bran, potatoes (with skin), salmon, spinach, and tuna.

4. Intravenous Treatments:

   • Intravenous calcium gluconate may be administered if the patient is at low risk of developing digitalis toxicity.

   • A 10% dextrose solution with 10 to 20 units of crystalline insulin per 1,000 mL may be given intravenously at a rate of 300 to 500 mL/hr.

   • Correction of acidosis, if present, can be achieved with intravenous sodium bicarbonate.

5. Dialysis: Hemodialysis or peritoneal dialysis may be necessary for severe cases of hyperkalemia.

6. Exchange Resins: While exchange resins may be utilized, they are not sufficient as a standalone treatment for acute hyperkalemia.

It is crucial to note that lowering potassium levels too rapidly in patients taking digitalis can lead to digitalis toxicity. Additionally, in patients with chronic renal failure or other conditions that impair potassium excretion, such as severe myocardial damage or heart failure, the use of potassium citrate should be avoided. If gastrointestinal symptoms such as severe vomiting, abdominal pain, or gastrointestinal bleeding occur, potassium citrate should be discontinued immediately, and the possibility of bowel perforation or obstruction should be investigated.

Nonclinical Toxicology

Teratogenic Effects

Animal reproduction studies have not been conducted for potassium citrate or Urocit-K. It is not known whether these compounds can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. Both potassium citrate and Urocit-K should be given to a pregnant woman only if clearly needed.

Non-Teratogenic Effects

The normal potassium ion content of human milk is approximately 13 mEq/L. It is not known if potassium citrate has an effect on this content. Potassium citrate should be administered to a breastfeeding woman only if clearly needed.

Nonclinical Toxicology

No specific details regarding nonclinical toxicology are provided in the inserts for potassium citrate or Urocit-K. Additionally, there are no specific details regarding animal pharmacology and toxicology for either compound.

Storage and Handling

Potassium Citrate is supplied in the form of Tablets and Extended Release Tablets.

It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F) as defined by USP Controlled Room Temperature.

The product must be kept in a tight container to maintain its integrity and efficacy.